Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS) by Ogawa, Satoshi et al.
Title
Design and baseline characteristics of the Xarelto Post-
Authorization Safety & Effectiveness Study in Japanese
Patients with Atrial Fibrillation (XAPASS)
Author(s)
Ogawa, Satoshi; Minematsu, Kazuo; Ikeda, Takanori;
Kitazono, Takanari; Nakagawara, Jyoji; Miyamoto, Susumu;
Murakawa, Yuji; Ohashi, Yohei; Takeichi, Makiko; Okayama,
Yutaka; Yamanaka, Satoshi; Inuyama, Lyo




© 2018 The Authors. Journal of Arrhythmia published by John
Wiley & Sons Australia, Ltd on behalf of the Japanese Heart
Rhythm Society. This is an open access article under the terms
of the Creative Commons Attribution‐NonCommercial
License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is




OR I G I N A L A R T I C L E
Design and baseline characteristics of the Xarelto Post-
Authorization Safety & Effectiveness Study in Japanese
Patients with Atrial Fibrillation (XAPASS)
Satoshi Ogawa MD, PhD1 | Kazuo Minematsu MD, PhD2 | Takanori Ikeda MD, PhD3 |
Takanari Kitazono MD, PhD4 | Jyoji Nakagawara MD, PhD5 | SusumuMiyamoto MD, PhD6 |
Yuji Murakawa MD, PhD7 | Yohei Ohashi MD, PhD8 | Makiko Takeichi PhD8 |
Yutaka Okayama BS8 | Satoshi Yamanaka MD, PhD8 | Lyo Inuyama MD8
1International University of Health &
Welfare Mita Hospital, Tokyo, Japan
2National Cerebral and Cardiovascular
Center, Suita, Osaka, Japan
3Department of Cardiovascular Medicine,
Faculty of Medicine, Toho University,
Tokyo, Japan
4Department of Medicine and Clinical
Science, Graduate School of Medical
Sciences, Kyushu University, Fukuoka,
Japan
5Integrative Cerebral and Cardiovascular
Imaging Center, National Cerebral and
Cardiovascular Center, Suita, Osaka, Japan
6Department of Neurosurgery, Kyoto
University Graduate School of Medicine,
Kyoto, Japan
7The 4th Department of Internal Medicine,
Teikyo University School of Medicine,
Mizonokuchi Hospital, Kawasaki, Japan
8Medical Affairs, Bayer Yakuhin, Ltd.,
Osaka, Japan
Correspondence
Satoshi Ogawa, International University of




The XAPASS is funded by Bayer Yakuhin
Ltd. (Osaka, Japan).
Abstract
Background: The phase III Japanese Rivaroxaban Once-Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (J-ROCKET AF) showed that the rivaroxaban
group had a lower event rate of intracranial bleeding than the warfarin group and
that rivaroxaban was noninferior to warfarin for the principal safety outcome. How-
ever, safety and effectiveness data from unselected patients with AF in everyday
clinical practice in Japan are lacking.
Methods: The Xarelto Post-Authorization Safety & Effectiveness Study in Japanese
Patients with Atrial Fibrillation (XAPASS) is a real-world, prospective, single-arm,
observational study mandated by the Japanese authority as postmarketing surveil-
lance. XAPASS involves patients with nonvalvular AF prescribed rivaroxaban. The
principal safety outcome is a composite of major and nonmajor bleeding events, and
the primary effectiveness outcome is the incidence of ischemic stroke, hemorrhagic
stroke, noncentral nervous system systemic embolism, and myocardial infarction.
Results: In total, 11 308 patients were enrolled from April 2012 to June 2014.
Their age was 73.1  9.9 years, and their CHADS2 score was 2.2  1.3. Female
patients, patients aged ≥75 years, patients with a body weight of ≤50 kg, and
patients with a creatinine clearance of <50 mL/min constituted 38.1%, 48.7%,
19.5%, and 23.9% of all patients, respectively. Almost half (53.2%) of patients were
prescribed other anticoagulants before starting rivaroxaban.
Conclusions: Data from this study will supplement those from the J-ROCKET AF
and provide practical information for the optimal use of rivaroxaban for stroke pre-
vention in Japanese patients with AF (Clinicaltrials.gov: NCT01582737).
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common sustained arrhythmia, and
its prevalence of approximately 1% in the Japanese population is
steadily increasing due to the country’s aging population.1–3 Without
anticoagulation, AF is associated with a fourfold to fivefold increase
in the risk of stroke.4,5 Although oral anticoagulants (OACs) effec-
tively reduce the risk of stroke in patients with AF, warfarin (the
only OAC available in Japan before 2011) has been underused in
real-world clinical practice because of significant clinical limitations
such as drug and food interactions and the need for frequent coagu-
lation monitoring. Since 2011, nonvitamin K antagonist OACs
(NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
have been approved in Japan for stroke prevention in patients with
nonvalvular AF (NVAF) and are now widely used in clinical practice
as recommended by the guidelines.6
One of these NOACs, rivaroxaban (BAY59-7939), is a novel, oral,
direct factor Xa inhibitor that inhibits thrombin formation via a dif-
ferent mechanism of action than that of warfarin. Rivaroxaban offers
benefits over warfarin such as a rapid onset of action, no require-
ment to conduct monitoring for dose adjustment, and fewer interac-
tions with food and concomitant drugs.7 In 2012, rivaroxaban
received regulatory approval in Japan for stroke prevention in
patients with NVAF based on the results of the phase III Japanese
Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation (J-ROCKET AF; NCT00494871)8 and
Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation (ROCKET AF; NCT00403767).9 The
ROCKET AF evaluated the safety and efficacy of rivaroxaban 20 mg
once daily (od) (15 mg od in patients with moderate renal impair-
ment, defined as a baseline creatinine clearance [CrCl] of 30-49 mL/
min) for the prevention of stroke and systemic embolism (SE) in
patients with NVAF. In contrast, 15 mg od (10 mg od in patients
with moderate renal impairment) was selected for phase III evalua-
tion in the J-ROCKET AF, according to differences in drug exposure
between Japanese and Caucasian patients and lower international
normalized ratio targets in Japanese clinical practice as recom-
mended by Japanese guidelines.
In the phase III J-ROCKET AF, rivaroxaban was compared with
dose-adjusted warfarin for the prevention of stroke and SE in high-
risk Japanese patients with NVAF. Rivaroxaban was noninferior to
warfarin for the principal safety outcome (hazard ratio [HR], 1.11;
95% confidence interval [CI], 0.87-1.42; Pnoninferiority < .001), and the
rivaroxaban group had a lower event rate of intracranial bleeding
than the warfarin group (0.8% vs 1.6%, respectively). There was a
strong trend for a lower rate of stroke/SE with rivaroxaban than
warfarin (HR, 0.49; 95% CI, 0.24-1.00; P = .050).
Postauthorization studies are needed to fully reveal the safety
and effectiveness of new agents in routine clinical practice. Because
of their strict design requirements, such as well-defined inclusion
and exclusion criteria, phase III clinical trials may not fully reflect the
characteristics observed in the broad range of patients seen in rou-
tine clinical practice. Therefore, this postmarketing surveillance reg-
istry was planned to explore the safety and effectiveness of
rivaroxaban in patients with NVAF in real-world clinical practice in
Japan. This article describes and discusses the study design and
baseline characteristics of the enrolled patients.
2 | METHODS
This postmarketing surveillance study was approved by the Ministry
of Health, Labour, and Welfare (MHLW) and will be carried out in
accordance with the standards for Good Post-marketing Study Prac-
tice provided by the MHLW in Japan.
2.1 | Objectives
The Xarelto Post-Authorization Safety & Effectiveness Study in Japa-
nese Patients with Atrial Fibrillation (XAPASS; NCT01582737) is a
real-world, prospective, postauthorization, observational study man-
dated by a Japanese regulatory authority, namely the Pharmaceuti-
cals and Medical Devices Agency, as postmarketing surveillance. In
contrast to the phase III J-ROCKET AF, the XAPASS procedures do
not interfere with the clinical management of patients with NVAF or
with the prescribing behaviors of attending physicians because study
is designed to assess the use of rivaroxaban in real-world clinical
practice. The key goal of the XAPASS is to confirm the safety profile
of rivaroxaban in real-world use in Japan across a broad range of
patients with NVAF.
2.2 | Study design
Xarelto Post-Authorization Safety & Effectiveness Study in Japanese
Patients with Atrial Fibrillation is an open-label, single-arm, observa-
tional, noninterventional cohort study (Figure 1). The standard obser-
vation period for each patient is 2 years; data are collected
6 months, 1 year, and 2 years after the initiation of rivaroxaban
treatment. After the completion of the standard observation period,
follow-up investigations are being conducted for a maximum of
5 years.
2.3 | Patient population
Eligible patients comprise men or women with NVAF starting
rivaroxaban therapy to reduce the risk of stroke/SE. Contraindica-
tions to rivaroxaban therapy were considered according to the Japa-
nese package insert.
2.4 | Drug administration
In Japan, rivaroxaban at 15 and 10 mg od is approved for patients
with a CrCl of ≥50 and <50 mL/min, respectively. Treating
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physicians prescribe rivaroxaban at their discretion, including the
dose (15 or 10 mg od) and duration of therapy. Any use of an anti-
coagulant or antiplatelet agent ≤30 days prior to rivaroxaban admin-
istration is documented in case report forms (CRFs), alongside details
of any medications or other therapies. The reasons for discontinua-
tion of rivaroxaban treatment and any follow-on therapy are docu-
mented in the CRF; any temporary interruptions of rivaroxaban
therapy are also documented.
2.5 | Baseline data
The baseline data collected were as follows.
1. Age, sex, body weight, height, smoking history, and any history
of allergy
2. History of NVAF including date of onset and type (paroxysmal,
persistent, or permanent)
3. Use of an anticoagulant or antiplatelet agent ≤30 days prior to
rivaroxaban administration
4. Other medical history
5. Vital signs and laboratory tests, if performed as part of routine
care
6. CrCl (mL/min)
7. Stroke and bleeding risk profiles based on risk scores such as
CHADS2 (congestive heart failure, hypertension, age, diabetes
mellitus, stroke), CHA2DS2-VASc (congestive heart failure, hyper-
tension, age of ≥75 years, diabetes mellitus, stroke, vascular dis-
ease, age of 65-74 years, sex category), or HAS-BLED
(hypertension, abnormal liver/renal function, stroke history,
bleeding predisposition, labile international normalized ratio,
elderly, drug/alcohol use)
8. Child-Pugh score
2.6 | Study outcomes
The primary outcomes are those that allow for assessment and esti-
mation of the safety of rivaroxaban in routine clinical practice, par-
ticularly in patients weighing ≤50 kg and those aged ≥75 years.
These outcomes will be recorded as adverse events (AEs) or serious
AEs, which will comprise bleeding events (major and nonmajor
bleeding events, principal safety outcome) and effectiveness events
(stroke [ischemic or hemorrhagic], noncentral nervous system SE,
or myocardial infarction, primary effectiveness outcome). Major
bleeding is defined as clinically overt bleeding associated with any of
the following: fatal outcome, involvement of a critical anatomic site
(intracranial, spinal, ocular, pericardial, articular, retroperitoneal, or
intramuscular with compartment syndrome), >2-g/dL reduction in
hemoglobin concentration, transfusion of >2 units of whole blood or
packed red blood cells, or permanent disability. Nonmajor bleeding is
defined as overt bleeding not meeting the criteria for major bleeding.
Stroke is defined as a new sudden, focal neurological deficit resulting
from a presumed cerebrovascular cause, persisting beyond 24 hours
and unattributable to another readily identifiable cause. Noncentral
nervous system SE is defined as abrupt vascular insufficiency associ-
ated with clinical or radiological evidence of arterial occlusion in the
absence of other likely mechanisms (eg, trauma, atherosclerosis, or
instrumentation). Myocardial infarction is defined as typical symp-
toms plus elevation in the levels of cardiac biomarkers (troponin I,
troponin T, or creatinine kinase-MB) above the upper limit of normal,
new pathological Q waves in ≥2 contiguous electrocardiographic
leads, or confirmation at autopsy.
Secondary outcomes include all-cause mortality, treatment per-
sistence with rivaroxaban, and rates of AEs or serious AEs across
patients with different baseline risk profiles for stroke or bleeding
(eg, CHADS2, CHA2DS2-VASc, or HAS-BLED), other baseline sub-
groups (eg, age, body weight, CrCl, use of antiplatelet agents, or
prior stroke/transient ischemic attack/noncentral nervous system
SE), and doses (15 or 10 mg).
2.7 | Statistical analysis plan
Statistical analyses are descriptive, exploratory, and generally limited
to frequency tables or summary statistics (eg, mean  standard
deviation or median  quartile for continuous variables and fre-
quency or percentage for categorical variables), for example, for
demographic data. Events of interest are presented as both raw inci-
dence proportions (patients with events/number of treated patients)
and incidence rates (eg, patients with events per 100 patient-years).
Each estimate is presented with the corresponding 95% CI. Kaplan-
Meier plots will show the time course up to the first event of inter-
est. Multivariate data analysis is also planned.
2.8 | Data management
Data from the XAPASS are captured in electronic CRFs, which com-
prise three parts. The investigating physician enters and transmits
F IGURE 1 The XAPASS single-arm,
prospective, observational design. Non-
CNS SE, noncentral nervous system
systemic embolism; NVAF, nonvalvular
atrial fibrillation
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the information for all targeted patients already enrolled as follows:
CRF 1 records patient background characteristics and the observa-
tion status for months 1-6, CRF 2 records the observation status for
months 7-12, and CRF 3 records the observation status for months
13-24. During the 5-year follow-up period, information is entered
and transmitted every 1 year after termination of the standard
observation period. If rivaroxaban therapy is discontinued, the obser-
vation period continues for a further 30 days. The XAPASS uses one
centralized database to receive results, and data are analyzed by an
independent data center. The data as of September 2017 were used
for this study.
2.9 | Administrative organization
The XAPASS is a postmarketing surveillance study funded by Bayer
Yakuhin Ltd. (Osaka, Japan) and conducted under the supervision of
a steering committee (Appendix A) that developed the protocol and
provides oversight of study execution, oversees the database, and is
accountable for analysis of the results and publications. Operational
oversight of the study will be performed through collaboration
between the steering committee and Bayer Yakuhin Ltd.
3 | RESULTS
3.1 | Baseline characteristics
In total, 11 308 Japanese patients with NVAF prescribed rivaroxaban
were enrolled from 1416 institutions from April 2012 to June 2014
(the date of the first patient’s first visit was 18 April 2012). Outpa-
tients constituted 84.6% of patients, while inpatients constituted
15.4%. Baseline characteristics are summarized in Table 1. The age
was 73.1  9.9 years, and 48.7% of patients were aged ≥75 years.
Female patients constituted 38.1%. The body weight was
60.9  12.6 kg, and 19.5% of patients had a body weight of ≤50 kg.
The body mass index was 23.7  3.8 kg/m2. The CrCl was
67.7  28.9 mL/min, and 23.9% of patients had a CrCl of <50 mL/
min. The CHADS2 score was 2.2  1.3. Patients with hypertension,
diabetes mellitus, previous stroke/transient ischemic attack, and con-
gestive heart failure constituted 74.3%, 22.3%, 23.7%, and 25.0% of
all patients, respectively. Among 6017 (53.2%) patients treated with
other anticoagulants prior to the administration of rivaroxaban, 3960
(65.8%), 1688 (28.1%), and 369 (6.1%) were treated with warfarin,
dabigatran, and other anticoagulants, respectively. Figure 2 shows
the histograms of age, body weight, CrCl, and CHADS2 score.
Table 1 also shows the baseline characteristics of 5396 (47.7%)
patients from clinics with ≤19 beds and 5912 (52.3%) patients from
hospitals with ≥20 beds. Patient characteristics according to geo-
graphic region are shown in Table S1.
3.2 | CHADS2 score in age or body weight groups
The CHADS2 score varied among age-groups (Figure 3A, Figure S1A).
More than 50% of <75-year-old patients had a CHADS2 score of
0-1. More patients aged ≥75 than <75 years had a CHADS2 score of
≥2, which is partially caused by the fact that an age of ≥75 years is
a risk factor for a higher CHADS2 score. Conversely, the CHADS2
score tended to gradually increase as body weight decreased (Fig-
ure 3B, Figure S1B). More than 70% of patients with a body weight
of <50 kg had a CHADS2 score of ≥2.
3.3 | Age and body weight
Patients with a body weight of ≤50 kg or age of ≥75 years are con-
sidered to have a high risk of bleeding and must be carefully
observed in the XAPASS as required by the Japanese health author-
ity. Among the 11 308 patients enrolled in the XAPASS, 19.5% had
a body weight of ≤50 kg and 48.7% had age of ≥75 years (Table 1).
As shown in Figure 4, 1641 patients (14.5%) had a body weight of
≤50 kg and age of ≥75 years.
3.4 | CrCl in age, body weight, or CHADS2 score
groups
The CrCl was examined in different age-groups (Figure 5, Fig-
ure S2). As age increased, the percentage of patients with a low
CrCl increased. Approximately half of patients aged 80-84 years
had a CrCl of <50 mL/min. The CrCl was also examined in differ-
ent body weight groups (Figure S3A, B) and CHADS2 score groups
(Figure S3C, D).
4 | DISCUSSION
The XAPASS is one of several postauthorization studies designed to
investigate the safety and effectiveness of rivaroxaban in patients
with NVAF in the real-world clinical setting among different global
regions. Outside Japan, the Xarelto for Prevention of Stroke in
Patients with Atrial Fibrillation (XANTUS) program is in progress.10
The XANTUS program comprises four studies: the XANTUS (Euro-
pean Union, plus enrollment in Canada; NCT01606995), XANTUS-EL
(Eastern Europe, Eastern Mediterranean, Middle East, Latin America;
NCT01800006), XANAP (Asia-Pacific; NCT01750788), and XAN-
TUS-CN (People’s Republic of China). The XANTUS (NCT01606995)
revealed a low real-world stroke incidence in patients receiving
rivaroxaban, with an annual stroke rate of 0.7% (compared with 1.7
events per 100 patient-years in the ROCKET AF on-treatment popu-
lation) and an incidence rate of major bleeding of 2.1 events per 100
patient-years, which is lower than that in the ROCKET AF (3.6
events per 100 patient-years).11 Other ongoing noninterventional
registries also provide real-world data on the effectiveness and
safety of rivaroxaban, including the Global Anticoagulant Registry in
the FIELD (GARFIELD)-AF,12 Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation (ORBIT)-AF,13 and the Dresden
NOAC Registry.14
Additional information on the real-world use of rivaroxaban in
patients with NVAF will be provided in the XAPASS. For instance,
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TABLE 1 Baseline characteristics
Characteristic All patients (N = 11 308)
Patients from clinics
with beds ≤19 (N = 5396)
Patients from hospitals
with beds ≥20 (N = 5912)
Age-y 73.1  9.9 73.2  9.8 73.1  9.9
<75 y-no. (%) 5804 (51.3) 2764 (51.2) 3040 (51.4)
≥75 y-no. (%) 5504 (48.7) 2632 (48.8) 2872 (48.6)
Female sex-no. (%) 4306 (38.1) 2125 (39.4) 2181 (36.9)
Height-cm 160.2  9.9 160.0  10.1 160.3  9.7
Body weight-kg 60.9  12.6 61.2  12.6 60.7  12.7
Body weight-no. (%)
≤50 kg 2209 (19.5) 1011 (18.7) 1198 (20.3)
>50 kg 8081 (71.5) 3887 (72.0) 4194 (70.9)
Unknown 1018 (9.0) 498 (9.2) 520 (8.8)
BMI-kg/m2 23.7  3.8 23.9  3.6 23.6  3.9
BMI-no. (%)
<18.5 615 (5.4) 228 (4.2) 387 (6.6)
18.5 to <25 5348 (47.3) 2495 (46.2) 2853 (48.3)
25 to <30 2493 (22.0) 1230 (22.8) 1263 (21.4)
≥30 483 (4.3) 232 (4.3) 251 (4.3)
Unknown 2369 (20.9) 1211 (22.4) 1158 (19.6)
Creatinine clearance-mL/min 67.7  28.9 68.5  31.2 67.0  26.5
Creatinine clearance-no. (%)
<15 mL/min 3 (0.03) 2 (0.04) 1 (0.02)
15 to < 30 mL/min 312 (2.8) 131 (2.4) 181 (3.1)
30 to < 50 mL/min 2382 (21.1) 1099 (20.4) 1283 (21.7)
50 to < 80 mL/min 4792 (42.4) 2278 (42.2) 2514 (42.5)
≥80 mL/min 2895 (25.6) 1428 (26.5) 1467 (24.8)
Unknown 924 (8.2) 458 (8.5) 466 (7.9)
CHADS2 score 2.2  1.3 2.1  1.3 2.3  1.3
CHADS2 score-no. (%)
0 985 (8.7) 498 (9.2) 487 (8.2)
1 2802 (24.8) 1439 (26.7) 1363 (23.1)
2 3400 (30.1) 1701 (31.5) 1699 (28.7)
3 2206 (19.5) 951 (17.6) 1255 (21.2)
4 1294 (11.4) 532 (9.9) 762 (12.9)
5 514 (4.5) 223 (4.1) 291 (4.9)
6 107 (0.9) 52 (1.0) 55 (0.9)
Baseline comorbidities-no. (%)
Hypertension 8405 (74.3) 4094 (75.9) 4311 (72.9)
Diabetes mellitus 2523 (22.3) 1182 (21.9) 1341 (22.7)
Previous stroke or transient ischemic attack 2675 (23.7) 995 (18.4) 1680 (28.4)
Congestive heart failure 2826 (25.0) 1351 (25.0) 1475 (24.9)
Switch from other anticoagulants-no. (%)
No 5291 (46.8) 2380 (44.1) 2911 (49.2)
Yes 6017 (53.2) 3016 (55.9) 3001 (50.8)
Warfarin 3960 (35.0) 1909 (35.4) 2051 (34.7)
Dabigatran 1688 (14.9) 915 (17.0) 773 (13.1)
Other 369 (3.3) 192 (3.6) 177 (3.0)
Plus-minus values are means SD.
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the study will reveal real-world situations of nonrecommended use
such as over- or underdosing of rivaroxaban with respect to renal
function. In Japan, the regular dosage of rivaroxaban is 15 mg od,
which is lower than the global recommended dosage of 20 mg od.
The Japanese medical package insert states that patients with a CrCl
of ≥50 mL/min (preserved renal function) should be prescribed
rivaroxaban 15 mg od and that patients with a CrCl of 15-49 mL/
min (moderate or severe renal impairment) should be prescribed a
dosage of 10 mg od. In real-world clinical practice, however, attend-
ing physicians usually determine the drug dosage for each patient
based on the patient’s characteristics and the physician’s clinical
experience, alongside the requirements in the medical package
insert. In the XANTUS, 15% of 3812 patients with a documented
CrCl of ≥50 mL/min received the lower rivaroxaban dosage of
15 mg od (the global reduced dosage for patients with NVAF with
moderate or severe renal impairment); conversely, a dosage of
20 mg od (the global recommended dosage for patients with NVAF
with preserved renal function) was received by 36% of the 640
patients who had moderate or severe renal impairment.11 Initial anal-
ysis of the XAPASS also showed that treatment was started at a
lower rivaroxaban dosage of 10 mg od in 252 (50.8%) of 496
patients whose CrCl was ≥50 mL/min.15 The effects of these non-
recommended uses of rivaroxaban on safety and effectiveness out-
comes will be reported.
F IGURE 2 Patient distributions in
different (A) age, (B) body weight, (C) CrCl,
and (D) CHADS2 score groups. CrCl,
creatinine clearance
F IGURE 3 CHADS2 score in different
(A) age and (B) body weight groups
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Treatment persistence with rivaroxaban will also be revealed in
the XAPASS. Treatment persistence is a major concern in stroke pre-
vention because discontinuation of anticoagulation therapy affects
the stroke risk in patients with AF.16 Persistence with rivaroxaban in
the XANTUS was 80% at 1 year.11 This is higher than in recent US
studies 17,18 but in line with the Dresden NOAC Registry, in which dis-
continuations of approximately 15% were recorded in the first year.19
Evaluation of effectiveness and safety of Xa inhibitor for the Pre-
vention of stroke And systemic embolism in a Nationwide cohort of
Japanese patients Diagnosed as non-valvular atrial fibrillation
(EXPAND; UMIN000009376) study20 is ongoing and will also pro-
vide real-world data on the effectiveness and safety of rivaroxaban.
The EXPAND study is an investigator-initiated clinical study based
on a collaborative contract between Tohoku University Hospital and
Bayer Yakuhin Ltd., which had no role in the study design, conduct
of the study, data collection, data analysis, or preparation or submis-
sion of the manuscript. The main objective of the EXPAND study
was to reveal the effectiveness and safety of rivaroxaban among
Japanese patients with AF, including patients who were not included
in the J-ROCKET AF (eg, patients with a CHADS2 score of 0 or 1),
in real-world clinical practice. The XAPASS is a real-world, prospec-
tive, observational study mandated by the Japanese authority as
postmarketing surveillance and conducted by Bayer Yakuhin Ltd.
under the supervision of a steering committee. The main objective
of the XAPASS was to confirm the safety profile of rivaroxaban in
real-world use in Japan across a broad range of patients with NVAF
through collection of AEs. Despite the differences in the study back-
ground/design and objective between the EXPAND study and
XAPASS, the results of these studies will complement and
strengthen each other as well as those of the phase III J-ROCKET
AF.
We herein report the baseline characteristics of the 11 308
patients enrolled in the XAPASS, which were clearly different from
those of the patients enrolled in the J-ROCKET AF. The low-risk
patients with a CHADS2 score of 0 or 1 were excluded from the J-
ROCKET AF8; in contrast, approximately one-third of patients
enrolled in the XAPASS had a CHADS2 score of 0 (8.7%) or 1
(24.8%). The distributions of the CHADS2 score were similar
between the XAPASS and EXPAND study,20 suggesting that these
results reflect the prescription pattern of rivaroxaban in Japan. It is
unclear why a large number of patients with a CHADS2 score of 0
and 1 were prescribed rivaroxaban despite the fact that the Japa-
nese guideline recommends rivaroxaban for patients with a CHADS2
score of ≥2. A recent subanalysis of the J-RHYTHM Registry sug-
gested that patients with lower CHADS2 scores benefit from antico-
agulation,21 which might lead to the prescription of rivaroxaban for
such patients. Compared with the XAPASS, the percentage of
patients with a CHADS2 score of 0 or 1 was higher in other AF reg-
istries such as the J-RHYTHM Registry (49.6%)22 and the SAKURA
AF Registry (43.3%).23 This might be explained by the fact that the
Japanese guideline recommends rivaroxaban for high-risk patients
with a CHADS2 score of ≥2.
There are some limitations to the XAPASS because of its open-
label, single-arm, prospective, observational design. First, the open-
label nature of the study means that selection bias cannot be
excluded because patients were enrolled with prior knowledge of
rivaroxaban treatment, which was administered at their physician’s
discretion. Second, because the study design is single-arm and there-
fore has no comparator drug such as warfarin, comparisons of differ-
ent treatments are not possible. Finally, the observational design
means that interference with patient management activities, such as
further laboratory or other investigations (eg, of CrCl), was not
permitted.
Strengths of the XAPASS include its large sample size (11 308
patients compared with 639 in the rivaroxaban arm of the
J-ROCKET AF)8 and prospective design, which allows for greater
completeness of and potentially higher quality data than studies with
retrospective designs.
The XAPASS is one of the largest AF registries in Japan. The 2-
year standard observation period ended in June 2016, and the maxi-
mum 5-year follow-up investigation will be completed in 2019. The
incidence of safety and effectiveness outcomes in patients with
NVAF treated with rivaroxaban in real-world clinical practice in
Japan will be clarified, and data on rivaroxaban use in a broad range
of patients will be available in follow-up studies. These include
F IGURE 4 Distribution of body weight in different age-groups.
The patient number is described on each bar
F IGURE 5 CrCl in different age-groups. CrCl, creatinine
clearance
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low- and high-risk patients, such as those with a CHADS2 score of 0
or 1, weighing ≤50 kg, and age of ≥75 years. These data will supple-
ment those from clinical trials, further clarifying optimal rivaroxaban
use in Japanese patients, and dissemination of the XAPASS findings
to clinical settings will be recommended.
5 | CONCLUSIONS
The XAPASS provides practical information for the optimum use of
rivaroxaban for stroke prevention in Japanese patients with AF
in real-world clinical settings and supplements the findings of the
J-ROCKET AF.
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